Am. J. Respir. Crit. Care Med., Volume 164, Number 4, August 2001, 569-574

Dose-dependent Effects of Inhaled Mometasone Furoate on Airway Function and Inflammation After Allergen Inhalation Challenge

MARK D. INMAN, RICHARD M. WATSON, TACY RERECICH, GAIL M. GAUVREAU, BARRY N. LUTSKY, PAUL STRYSZAK, and PAUL M. O'BYRNE

Asthma Research Group, McMaster University, Hamilton, Ontario, Canada; and Schering Plough Research Institute, Kenilworth, New Jersey

Comparisons of the potency of different inhaled corticosteroids, delivery devices, and treatment regimens in the management of asthma can only be made when outcome measurements display a dose-dependent effect. These outcomes have been difficult to identify. In this study, we compared in a randomized, double-blind, crossover design, the effects of 6 d treatment with placebo and three doses (50, 100, and 400 µg, twice daily) of mometasone furoate delivered by dry powder inhaler (MF-DPI) on responses after allergen inhalation challenge. Twelve mild asthmatic subjects with dual responses after allergen inhalation were studied. Outcome measurements included early and late asthmatic responses, the change in methacholine airway responsiveness 24 h after challenge, and sputum eosinophilia measured 7 and 24 h after challenge. All three doses of MF-DPI demonstrated similar attenuation of early responses and allergen-induced airway hyperresponsiveness relative to placebo (p < 0.05). The late maximal %fall in FEV₁ after placebo treatment was 23.5% and was significantly reduced in a dose-dependent manner to 12.3%, 11.0%, and 5.9% for the 50-, 100-, and 400-µg twice-daily treatments (p = 0.007). The allergen-induced increase in sputum eosinophilia (×10⁴ cells/ml) 24 h after challenge during placebo treatment was 60.2 and was significantly reduced to 24.0, 15.3, and 6.2 for the 50-, 100-, and 400-µg twice-daily treatments. MF-DPI is effective at attenuating allergen-induced early and late responses, airway hyperresponsiveness, and sputum eosinophilia, and dose-response effects exist for the attenuation of the late response.

Keywords: asthma; allergen-challenge; inflammation; corticosteroid

This article has been cited by other articles:

				D. S. Southam, R. Ellis, J. Wattie, S. Young, and M. D. Inman Budesonide prevents but does not reverse sustained airway hyperresponsiveness in mice Eur. Respir. J., October 1, 2008; 32(4): 970 - 978. [Abstract] [Full Text] [PDF]

				R. Leigh, D. Vethanayagam, M. Yoshida, R. M. Watson, T. Rerecich, M. D. Inman, and P. M. O'Byrne Effects of Montelukast and Budesonide on Airway Responses and Airway Inflammation in Asthma Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1212 - 1217. [Abstract] [Full Text] [PDF]

				N.J. Vanacker, E. Palmans, R.A. Pauwels, and J.C. Kips Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats Eur. Respir. J., October 1, 2002; 20(4): 873 - 879. [Abstract] [Full Text] [PDF]

				S A Kharitonov, L E Donnelly, P Montuschi, M Corradi, J V Collins, and P J Barnes Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma Thorax, October 1, 2002; 57(10): 889 - 896. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 598 - 618. [Full Text] [PDF]

				P G Gibson, M Fujimura, and A Niimi Eosinophilic bronchitis: clinical manifestations and implications for treatment Thorax, February 1, 2002; 57(2): 178 - 182. [Abstract] [Full Text] [PDF]